Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
International Psoriasis Council
subscribe
Search

Advancing Knowledge. Improving Care.

PDS Partner Symposium 2026

IPC-PDS Joint Symposium: Lessons from the Bench to Bedside in Psoriasis

POLISH DERMATOLOGICAL SOCIETY CONFERENCE | RZESZÓW, POLAND

February 26, 2026
 | 12: 00 – 14:00 CET

Add this event to your calendar

Apple Google Outlook Outlook.com Office 365 Yahoo

Agenda

WELCOME AND INTRODUCTION
Adam Reich, MD, PhD, Poland

Inflammatory Endotypes of Psoriasis
Curdin Conrad, MD, Switzerland

Reconciling Clinical Immunophenotypes of Psoriasis
Josep Riera-Monroig, MD, Spain

Pathomechanistic Background of Mental Diseases in Psoriasis
Maria-Angeliki Gkini, MD, MSc, PhD, FRCP, United Kingdom

Neuroimmunological Axis and Pruritus in Psoriasis
Manuel P. Pereira, MD, PhD, Germany

Can We Decrease Stigma in Psoriasis?
Adam Reich, MD, PhD, Poland

Personalized Care in Psoriasis
Peter van de Kerkhof, MD, PhD, Netherlands

Panel Discussion
All Faculty

Closing and Adjourn
Adam Reich, MD, PhD, Poland

Program Chair

Adam Reich, MD, PhD

University of Rzeszów

Rzeszów, Poland

IPC Councilor

Bio

Program Faculty

Curdin Conrad, MD

University Hospital of Lausanne

Lausanne, Switzerland

IPC Board Member

Bio

Maria-Angeliki Gkini, MD, MSc, PhD, FRCP

Barts Health NHS Trust and Queen Mary University

London, United Kingdom

IPC Jr. Councilor

Bio

Josep Riera-Monroig, MD

Hospital Clínic de Barcelona

Barcelona, Spain

IPC Jr. Councilor

Bio

Peter van de Kerkhof, MD, PhD

International Psoriasis Council

Nijmegen, Netherlands

IPC Chief Medical Officer

Bio

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026